ClearBridge Investments
RARE icon

ClearBridge Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

ClearBridge Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-155,752
Closed -$4.69M – 732
2025
Q3 		$4.69M Sell
155,752
-1,984,825
-93% -$59.5M ﹤0.01% 596
2025
Q2 		$77.8M Sell
2,140,577
-119,128
-5% -$4.29M 0.06% 258
2025
Q1 		$81.8M Sell
2,259,705
-62,500
-3% -$2.6M 0.07% 246
2024
Q4 		$97.7M Sell
2,322,205
-104,772
-4% -$5.2M 0.08% 236
2024
Q3 		$135M Buy
2,426,977
+73,173
+3% +$3.73M 0.11% 185
2024
Q2 		$96.7M Sell
2,353,804
-47,050
-2% -$2.01M 0.08% 234
2024
Q1 		$112M Buy
2,400,854
+17,362
+0.7% +$819K 0.09% 237
2023
Q4 		$114M Buy
2,383,492
+89,922
+4% +$3.49M 0.1% 216
2023
Q3 		$81.8M Sell
2,293,570
-469,676
-17% -$18.6M 0.08% 241
2023
Q2 		$127M Buy
2,763,246
+62,169
+2% +$2.88M 0.12% 181
2023
Q1 		$108M Buy
2,701,077
+6,635
+0.2% +$285K 0.1% 193
2022
Q4 		$125M Sell
2,694,442
-68,380
-2% -$2.69M 0.12% 166
2022
Q3 		$114M Sell
2,762,822
-74,321
-3% -$3.82M 0.12% 171
2022
Q2 		$169M Sell
2,837,143
-26,778
-0.9% -$1.65M 0.16% 135
2022
Q1 		$208M Buy
2,863,921
+85,062
+3% +$5.92M 0.16% 143
2021
Q4 		$234M Buy
2,778,859
+413,238
+17% +$33.6M 0.16% 137
2021
Q3 		$213M Sell
2,365,621
-4,899
-0.2% -$443K 0.15% 147
2021
Q2 		$226M Buy
2,370,520
+467,125
+25% +$48.7M 0.16% 143
2021
Q1 		$217M Buy
1,903,395
+28,078
+1% +$3.82M 0.16% 136
2020
Q4 		$260M Buy
1,875,317
+96,339
+5% +$11.4M 0.2% 111
2020
Q3 		$146M Buy
1,778,978
+12,416
+0.7% +$1.03M 0.13% 148
2020
Q2 		$138M Buy
1,766,562
+537,252
+44% +$35.6M 0.12% 150
2020
Q1 		$54.6M Buy
1,229,310
+53,536
+5% +$2.78M 0.06% 236
2019
Q4 		$50.7M Sell
1,175,774
-206,003
-15% -$8.5M 0.04% 325
2019
Q3 		$59.1M Buy
1,381,777
+373,904
+37% +$20.3M 0.05% 289
2019
Q2 		$64M Sell
1,007,873
-5,400
-0.5% -$344K 0.06% 266
2019
Q1 		$70.3M Buy
1,013,273
+3,237
+0.3% +$185K 0.06% 250
2018
Q4 		$43.9M Buy
1,010,036
+164
+0% +$8.96K 0.04% 314
2018
Q3 		$77.1M Buy
1,009,872
+53,460
+6% +$4.35M 0.07% 248
2018
Q2 		$73.5M Buy
956,412
+161,824
+20% +$10.5M 0.06% 252
2018
Q1 		$40.5M Buy
794,588
+790,168
+17,877% +$39.8M 0.04% 335
2017
Q4 		$205K Sell
4,420
-5
-0.1% -$245 ﹤0.01% 746
2017
Q3 		$236K Buy
4,425
+28
+0.6% +$1.66K ﹤0.01% 734
2017
Q2 		$273K Buy
4,397
+1,622
+58% +$97.7K ﹤0.01% 723
2017
Q1 		$188K Sell
2,775
-35
-1% -$2.67K ﹤0.01% 775
2016
Q4 		$198K Buy
2,810
+80
+3% +$5.68K ﹤0.01% 787
2016
Q3 		$194K Sell
2,730
-2
-0.1% -$128 ﹤0.01% 775
2016
Q2 		$134K Buy
2,732
+1,510
+124% +$97.7K ﹤0.01% 800
2016
Q1 		$77K Buy
1,222
+1,052
+619% +$68.8K ﹤0.01% 848
2015
Q4 		$19K Buy
+170
New +$17K ﹤0.01% 982

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ClearBridge Investments's RARE Position: Q4 2025 in Review

ClearBridge Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 155,752 shares — an estimated $4.69M sold.

ClearBridge Investments first reported a position in RARE in Q4 2015 and held it in 40 quarters. The position peaked at $260M in Q4 2020. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • ClearBridge Investments reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • ClearBridge Investments sold 155,752 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $4.69M.
  • ClearBridge Investments first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 40 quarters.
  • ClearBridge Investments's Ultragenyx Pharmaceutical position peaked at $260M in Q4 2020.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on ClearBridge Investments's 13F filing for Q4 2025, filed 11 Feb 2026.